​

Funding Round

Series A - Perfuze

Series A - Perfuze

Investment Firm

Overview

Perfuze is developing innovative medical technology to treat acute ischemic stroke.

Announced Date

Feb 09, 2022

Funding Type

Series A

Highlights

Location

Europe

Social

Investor Lead

Seroba Life Sciences

Seroba Life Sciences

Seroba Life Sciences is a early_stage_venture firm.

EQT Life Sciences

EQT Life Sciences

EQT Life Sciences is a debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

5

Investor Name
Participant InvestorEarlyBird
Participant InvestorMedtech Convergence Fund
Participant InvestorEQT Life Sciences
Participant InvestorSeroba Life Sciences
Participant InvestorSV Health Investors

Round Details and Background

Perfuze raised $25698367 on 2022-02-09 in Series A

Perfuze is developing innovative medical technology to treat acute ischemic stroke.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 29, 2019
Seed Round - Perfuze
3-3.4M
Feb 09, 2022
Series A - Perfuze
7-25.7M

Recent Activity

There is no recent news or activity for this profile.